• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

    8/3/22 10:38:04 AM ET
    $AAWW
    $AINV
    $ATHE
    $CAT
    Transportation Services
    Consumer Discretionary
    Finance/Investors Services
    Finance
    Get the next $AAWW alert in real time by email

     

    Upgrades

    • Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-ago quarter. The stock has a 52-week-high of $80.30 and a 52-week-low of $41.69. At the end of the last trading period, Cognex closed at $49.72.
    • According to RBC Capital, the prior rating for Sealed Air Corp (NYSE:SEE) was changed from Sector Perform to Outperform. In the second quarter, Sealed Air showed an EPS of $1.01, compared to $0.79 from the year-ago quarter. The stock has a 52-week-high of $70.72 and a 52-week-low of $55.08. At the end of the last trading period, Sealed Air closed at $56.17.
    • RBC Capital upgraded the previous rating for Clearwater Paper Corp (NYSE:CLW) from Sector Perform to Outperform. In the second quarter, Clearwater Paper showed an EPS of $1.11, compared to $1.07 from the year-ago quarter. At the moment, the stock has a 52-week-high of $38.88 and a 52-week-low of $25.07. Clearwater Paper closed at $34.80 at the end of the last trading period.
    • Citigroup upgraded the previous rating for The Mosaic Co (NYSE:MOS) from Neutral to Buy. Mosaic earned $3.64 in the second quarter, compared to $1.17 in the year-ago quarter. The stock has a 52-week-high of $79.28 and a 52-week-low of $37.08. At the end of the last trading period, Mosaic closed at $52.22.
    • Raymond James upgraded the previous rating for Uber Technologies Inc (NYSE:UBER) from Market Perform to Outperform. For the second quarter, Uber Technologies had an EPS of $0.47, compared to year-ago quarter EPS of $0.38. The current stock performance of Uber Technologies shows a 52-week-high of $45.90 and a 52-week-low of $19.89. Moreover, at the end of the last trading period, the closing price was at $29.25.
    • For Xylem Inc (NYSE:XYL), Credit Suisse upgraded the previous rating of Underperform to Neutral. Xylem earned $0.66 in the second quarter, compared to $0.66 in the year-ago quarter. The current stock performance of Xylem shows a 52-week-high of $121.05 and a 52-week-low of $72.08. Moreover, at the end of the last trading period, the closing price was at $95.37.
    • For CF Industries Holdings Inc (NYSE:CF), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, CF Industries Holdings had an EPS of $6.19, compared to year-ago quarter EPS of $1.14. The current stock performance of CF Industries Holdings shows a 52-week-high of $113.48 and a 52-week-low of $63.10. Moreover, at the end of the last trading period, the closing price was at $98.17.
    • For Atlas Air Worldwide Holdings Inc (NASDAQ:AAWW), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. In the first quarter, Atlas Air Worldwide Hldgs showed an EPS of $2.99, compared to $2.45 from the year-ago quarter. The current stock performance of Atlas Air Worldwide Hldgs shows a 52-week-high of $97.13 and a 52-week-low of $58.70. Moreover, at the end of the last trading period, the closing price was at $87.37.

    See all analyst ratings upgrades.

     

    Downgrades

    • According to B. Riley Securities, the prior rating for Sierra Wireless Inc (NASDAQ:SWIR) was changed from Buy to Neutral. In the first quarter, Sierra Wireless showed an EPS of $0.23, compared to $0.26 from the year-ago quarter. The current stock performance of Sierra Wireless shows a 52-week-high of $30.69 and a 52-week-low of $13.44. Moreover, at the end of the last trading period, the closing price was at $28.15.
    • Macquarie downgraded the previous rating for XPeng Inc (NYSE:XPEV) from Outperform to Neutral. XPeng earned $0.28 in the first quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $51.50 and a 52-week-low of $18.01. At the end of the last trading period, XPeng closed at $24.15.
    • William Blair downgraded the previous rating for Sierra Wireless Inc (NASDAQ:SWIR) from Outperform to Market Perform. In the first quarter, Sierra Wireless showed an EPS of $0.23, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of $30.69 and a 52-week-low of $13.44. At the end of the last trading period, Sierra Wireless closed at $28.15.
    • According to Needham, the prior rating for Semtech Corp (NASDAQ:SMTC) was changed from Buy to Hold. Semtech earned $0.80 in the first quarter, compared to $0.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $92.14 and a 52-week-low of $49.91. Semtech closed at $55.34 at the end of the last trading period.
    • According to Guggenheim, the prior rating for Incyte Corp (NASDAQ:INCY) was changed from Buy to Neutral. Incyte earned $1.01 in the second quarter, compared to $0.80 in the year-ago quarter. At the moment, the stock has a 52-week-high of $84.86 and a 52-week-low of $65.07. Incyte closed at $72.58 at the end of the last trading period.
    • For Caterpillar Inc (NYSE:CAT), Bernstein downgraded the previous rating of Outperform to Market Perform. In the second quarter, Caterpillar showed an EPS of $3.18, compared to $2.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $237.90 and a 52-week-low of $167.08. Caterpillar closed at $183.51 at the end of the last trading period.
    • According to Stephens & Co., the prior rating for Cognex Corp (NASDAQ:CGNX) was changed from Overweight to Equal-Weight. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-ago quarter. The stock has a 52-week-high of $80.30 and a 52-week-low of $41.69. At the end of the last trading period, Cognex closed at $49.72.
    • Canaccord Genuity downgraded the previous rating for Sierra Wireless Inc (NASDAQ:SWIR) from Buy to Hold. In the first quarter, Sierra Wireless showed an EPS of $0.23, compared to $0.26 from the year-ago quarter. The current stock performance of Sierra Wireless shows a 52-week-high of $30.69 and a 52-week-low of $13.44. Moreover, at the end of the last trading period, the closing price was at $28.15.
    • According to JP Morgan, the prior rating for Hydrofarm Holdings Group Inc (NASDAQ:HYFM) was changed from Overweight to Neutral. In the first quarter, Hydrofarm Holdings Group showed an EPS of $0.17, compared to $0.19 from the year-ago quarter. The stock has a 52-week-high of $29.14 and a 52-week-low of $2.96. At the end of the last trading period, Hydrofarm Holdings Group closed at $3.27.
    • According to Credit Suisse, the prior rating for Esperion Therapeutics Inc (NASDAQ:ESPR) was changed from Neutral to Underperform. In the second quarter, Esperion Therapeutics showed an EPS of $1.05, compared to $1.67 from the year-ago quarter. At the moment, the stock has a 52-week-high of $7.13 and a 52-week-low of $3.28. Esperion Therapeutics closed at $5.87 at the end of the last trading period.
    • According to Roth Capital, the prior rating for Knowles Corp (NYSE:KN) was changed from Buy to Neutral. Knowles earned $0.33 in the second quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $23.81 and a 52-week-low of $16.59. At the end of the last trading period, Knowles closed at $19.07.

    See all analyst ratings downgrades.

     

    Initiations

    • Argus Research initiated coverage on WR Berkley Corp (NYSE:WRB) with a Buy rating. The price target for WR Berkley is set to $72.00. In the second quarter, WR Berkley showed an EPS of $1.12, compared to $1.17 from the year-ago quarter. The current stock performance of WR Berkley shows a 52-week-high of $99.68 and a 52-week-low of $60.94. Moreover, at the end of the last trading period, the closing price was at $61.11.
    • With a Buy rating, DA Davidson initiated coverage on FiscalNote Holdings Inc (NYSE:NOTE). The price target seems to have been set at $8.50 for FiscalNote Holdings. At the moment, the stock has a 52-week-high of $9.25 and a 52-week-low of $5.55. FiscalNote Holdings closed at $6.93 at the end of the last trading period.
    • With a Buy rating, Jefferies initiated coverage on ImmunityBio Inc (NASDAQ:IBRX). The price target seems to have been set at $8.00 for ImmunityBio. For the first quarter, ImmunityBio had an EPS of $0.26, compared to year-ago quarter EPS of $0.21. The current stock performance of ImmunityBio shows a 52-week-high of $7.85 and a 52-week-low of $2.60. Moreover, at the end of the last trading period, the closing price was at $3.73.
    • Barclays initiated coverage on Reinsurance Group of America Inc (NYSE:RGA) with a Equal-Weight rating. The price target for Reinsurance Group is set to $120.00. For the first quarter, Reinsurance Group had an EPS of $0.47, compared to year-ago quarter EPS of $1.24. At the moment, the stock has a 52-week-high of $127.22 and a 52-week-low of $97.61. Reinsurance Group closed at $113.55 at the end of the last trading period.
    • With a Buy rating, Ladenburg Thalmann initiated coverage on Alterity Therapeutics Ltd (NASDAQ:ATHE). The price target seems to have been set at $2.00 for Alterity Therapeutics. The stock has a 52-week-high of $1.23 and a 52-week-low of $0.56. At the end of the last trading period, Alterity Therapeutics closed at $0.60.
    • With a Buy rating, HC Wainwright & Co. initiated coverage on Valneva SE (NASDAQ:VALN). The price target seems to have been set at $34.00 for Valneva. For the first quarter, Valneva had an EPS of $0.52, compared to year-ago quarter EPS of $0.72. The current stock performance of Valneva shows a 52-week-high of $53.11 and a 52-week-low of $13.71. Moreover, at the end of the last trading period, the closing price was at $19.84.
    • With an Overweight rating, Stephens & Co. initiated coverage on ModivCare Inc (NASDAQ:MODV). The price target seems to have been set at $145.00 for ModivCare. For the first quarter, ModivCare had an EPS of $1.57, compared to year-ago quarter EPS of $1.92. The stock has a 52-week-high of $148.46 and a 52-week-low of $80.55. At the end of the last trading period, ModivCare closed at $101.59.
    • With a Buy rating, Goldman Sachs initiated coverage on Kymera Therapeutics Inc (NASDAQ:KYMR). The price target seems to have been set at $40.00 for Kymera Therapeutics. For the first quarter, Kymera Therapeutics had an EPS of $0.71, compared to year-ago quarter EPS of $0.29. At the moment, the stock has a 52-week-high of $65.44 and a 52-week-low of $13.15. Kymera Therapeutics closed at $22.75 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $AAWW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAWW
    $AINV
    $ATHE
    $CAT

    CompanyDatePrice TargetRatingAnalyst
    Incyte Corp.
    $INCY
    2/5/2026$135.00Buy
    H.C. Wainwright
    Uber Technologies Inc.
    $UBER
    2/4/2026$100.00Mkt Perform → Mkt Outperform
    Citizens JMP
    CF Industries Holdings Inc.
    $CF
    2/4/2026$72.00Neutral → Sell
    Rothschild & Co Redburn
    Mosaic Company
    $MOS
    2/2/2026$36.00Sector Perform → Sector Outperform
    Scotiabank
    Kymera Therapeutics Inc.
    $KYMR
    1/28/2026$133.00Overweight
    Barclays
    Xylem Inc.
    $XYL
    1/26/2026Outperform
    William Blair
    Clearwater Paper Corporation
    $CLW
    1/20/2026$21.00Hold
    Truist
    W.R. Berkley Corporation
    $WRB
    1/20/2026$55.00Hold → Sell
    TD Cowen
    More analyst ratings

    $AAWW
    $AINV
    $ATHE
    $CAT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAWW
    $AINV
    $ATHE
    $CAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $2,835,251 worth of shares (40,000 units at $70.88) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/6/26 8:46:48 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $21,451,897 worth of shares (315,221 units at $68.05) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/4/26 7:45:14 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Director Brice Todd D bought $18,230 worth of shares (1,000 units at $18.23), increasing direct ownership by 8% to 13,500 units (SEC Form 4)

    4 - FIRST COMMONWEALTH FINANCIAL CORP /PA/ (0000712537) (Issuer)

    2/3/26 2:44:34 PM ET
    $FCF
    Major Banks
    Finance

    $AAWW
    $AINV
    $ATHE
    $CAT
    SEC Filings

    View All

    SEC Form 144 filed by Knowles Corporation

    144 - Knowles Corp (0001587523) (Subject)

    2/10/26 4:05:09 PM ET
    $KN
    Consumer Electronics/Appliances
    Consumer Staples

    SEC Form 10-K filed by Incyte Corp.

    10-K - INCYTE CORP (0000879169) (Filer)

    2/10/26 4:01:52 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.

    SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    2/10/26 11:17:43 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAWW
    $AINV
    $ATHE
    $CAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Har

    2/10/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cognex Announces Participation at Upcoming Investor Conferences

    NATICK, Mass., Feb. 10, 2026 /PRNewswire/ -- Cognex Corporation (NASDAQ:CGNX), the global technology leader in industrial machine vision, today announced that its Chief Financial Officer, Dennis Fehr, is scheduled to present at the following upcoming investor conferences: The Barclays 43rd Annual Industrial Select Conference in Miami, Florida on Wednesday, February 18, 2026, at 1:50 p.m. Eastern Standard Time.The Citi 2026 Global Industrial Tech and Mobility Conference in Miami, Florida on Thursday, February 19, 2026, at 8:50 a.m. Eastern Standard Time.The live webcasts and su

    2/10/26 8:00:00 AM ET
    $CGNX
    Industrial Machinery/Components
    Industrials

    Baidu and Uber Partner to Bring Apollo Go Autonomous Ride-hailing to Dubai in Collaboration with Dubai's Roads and Transport Authority

    Baidu, Inc. (NASDAQ:BIDU) and Uber Technologies, Inc. (NYSE:UBER), in partnership with Dubai's Roads and Transport Authority (RTA), today announced the next phase of their global partnership, bringing the Apollo Go autonomous ride-hailing service to the Uber platform in Dubai. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210608046/en/Baidu and Uber Partner to Bring Apollo Go Autonomous Ride-hailing to Dubai Expected to launch in the coming month, the fully autonomous vehicles will be available via the Uber app across select locations within the Jumeirah area, and the deployment will expand based on operational learnings and

    2/10/26 7:57:00 AM ET
    $BIDU
    $UBER
    Computer Software: Programming Data Processing
    Technology
    Real Estate

    $AAWW
    $AINV
    $ATHE
    $CAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Incyte with a new price target

    H.C. Wainwright initiated coverage of Incyte with a rating of Buy and set a new price target of $135.00

    2/5/26 6:58:02 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Uber upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Uber from Mkt Perform to Mkt Outperform and set a new price target of $100.00

    2/4/26 3:42:11 PM ET
    $UBER
    Real Estate

    CF Industries downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded CF Industries from Neutral to Sell and set a new price target of $72.00

    2/4/26 8:27:16 AM ET
    $CF
    Agricultural Chemicals
    Industrials

    $AAWW
    $AINV
    $ATHE
    $CAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel & Sec Perna Robert J covered exercise/tax liability with 2,946 shares and sold $85,767 worth of shares (3,166 units at $27.09), decreasing direct ownership by 9% to 60,440 units (SEC Form 4)

    4 - Knowles Corp (0001587523) (Issuer)

    2/10/26 12:47:07 PM ET
    $KN
    Consumer Electronics/Appliances
    Consumer Staples

    President & CEO Niew Jeffrey covered exercise/tax liability with 13,744 shares, decreasing direct ownership by 2% to 725,626 units (SEC Form 4)

    4 - Knowles Corp (0001587523) (Issuer)

    2/10/26 12:46:06 PM ET
    $KN
    Consumer Electronics/Appliances
    Consumer Staples

    Senior Vice President & COO Giesecke Daniel J. covered exercise/tax liability with 3,332 shares and sold $432,390 worth of shares (15,885 units at $27.22), decreasing direct ownership by 10% to 164,963 units (SEC Form 4)

    4 - Knowles Corp (0001587523) (Issuer)

    2/10/26 12:45:17 PM ET
    $KN
    Consumer Electronics/Appliances
    Consumer Staples

    $AAWW
    $AINV
    $ATHE
    $CAT
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Caterpillar Announces Leadership Transition in Construction Industries

    IRVING, Texas, Jan. 14, 2026 /PRNewswire/ -- Caterpillar Inc. (NYSE:CAT) today announced that Tony Fassino, group president of Construction Industries, has elected to retire effective May 31, 2026, following 30 years with the company. Caterpillar veteran Rod Shurman has been appointed group president of Construction Industries effective Feb. 1, 2026, at which time Fassino will become group president, retired, for the remainder of the transition. "Tony's many contributions to Caterpillar and our customers' success over his accomplished 30-year career will leave a lasting impact

    1/14/26 4:05:00 PM ET
    $CAT
    Construction/Ag Equipment/Trucks
    Industrials

    $AAWW
    $AINV
    $ATHE
    $CAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 9:05:42 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/13/24 5:07:48 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ModivCare Inc.

    SC 13D/A - ModivCare Inc (0001220754) (Subject)

    12/9/24 7:46:13 PM ET
    $MODV
    Transportation Services
    Consumer Discretionary

    $AAWW
    $AINV
    $ATHE
    $CAT
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Har

    2/10/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

    Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net product revenue of $1.22 billion (+20% Y/Y) in the fourth quarter 2025 and $4.35 billion (+20%) for the full year 2025, exceeding full year 2025 net product revenue guidance of $4.23 - $4.32 billion Provides full year 2026 total net product revenue guidance range of $4.77 - $4.94 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance. "Our fourth quarter and full year 2025 result

    2/10/26 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Xylem Reports Fourth Quarter and Full Year 2025 Results

    Fourth-Quarter Highlights Orders of $2.4 billion, up 9% on a reported basis and 7% organically Revenue of $2.4 billion, up 6% on a reported basis and 4% organically Earnings per share of $1.37, up 2%; $1.42 on an adjusted basis, up 20% Full-Year Highlights Revenue of $9.0 billion, up 6% on a reported basis and 5% organically Earnings per share of $3.92, up 7%; $5.08 on an adjusted basis, up 19% Initiating 2026 full-year revenue guidance of $9.1 to $9.2 billion, up 2% to 4% organically, and adjusted earnings per share of $5.35 to $5.60 Xylem Inc. (NYSE:XYL), a leading global water solutions company dedicated to solving the world's most challenging water issues, today

    2/10/26 6:55:00 AM ET
    $XYL
    Fluid Controls
    Industrials